BioCryst Pharmaceuticals Inc

BioCryst insider buys and sells reveal a balanced, confidence‑driven strategy amid rising rare‑disease pipeline buzz and potential upside.

BioCryst’s new R&D chief, Sandeep Menon, receives a $646k‑worth stock‑grant, signaling strong insider confidence and a potential catalyst for share gains as the rare‑disease pipeline accelerates.

Insider buying sparks buzz at BioCryst: Theresa Heggie’s $6.30 purchase hints at confidence in the drug pipeline, potentially driving the stock toward its 52‑week high.

BioCryst insider buy‑sell: Legal Officer Barnes Alane P buys shares at $5.51 and sells at $9.15, signaling long‑term confidence and a subtle bullish cue for investors.

BioCryst insiders buy shares amid a 52‑week high – insider Milne’s recent purchase signals confidence in the company’s rare‑disease pipeline and growth prospects.

Insider holdings at BioCryst reveal cautious confidence: CCO holds 258k shares, while exec sales hint at volatility; investors should watch upcoming milestones.